PFE - Pfizer Stock Rises on Upbeat RSV Vaccine Trial Data | Benzinga
Pfizer Inc (NYSE: PFE) stock is up 1.7% at $27.04 at last check, following news a late-stage trial of its respiratory syncytial virus (RSV) vaccine Abrysvo generated an immune response in higher risk adults under the age of 60. The company plans to seek expanded approval of the vaccine for ages ...